Sangui Biotech International, Inc. Reports Sales Results for the Fiscal Year of 2019
October 09, 2019 at 08:53 am EDT
Share
Sangui Biotech International, Inc. reported sales results for the fiscal year of 2019. For the period, the company achieved revenues from royalty income and product sales of USD 88,001. In the same period of the previous year the comparable revenue amounted to USD 77,152. Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2019 increased by 14% compared to previous year.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
